Download a copy of our poster titled, 'A Phase I, open-label, 2-Part study to establish absolute bioavailability'. A Phase I, open-label, 2-Part study to establish absolute bioavailability and the ADME of evogliptin in healthy male subjects by light-label approach.

Absorption, metabolism and excretion of [14C]-gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Download a copy of our poster from ISSX 2016 entitled, 'Absorption, metabolism, and excretion of [14C]-gemigliptin'.

Download our poster that reports on a new real-time adaptive GMP manufacturing paradigm serving patient and study needs
by delivering personalized drug products on demand.

The efficiency and effectiveness of new drug development has remained problematic over the last decade. Our Translational Pharmaceutics® platform improves R&D productivity.

Download our poster titled, 'Application of Translational Pharmaceutics to Reduce Time, Cost, and Risk in the Early Development of Inhaled Drug Products.'

Conduct of clinical ADME study for Vosaroxin in oncology patients via real-time adaptive manufacture of intravenous drug product.

Download a copy of our AAPS 2015 poster titled, 'Conduct of clinical ADME study for Vosaroxin in oncology patients'.

The key objectives of Human ADME studies are to evaluate mass balance, determine the routes and rates of elimination, and gain an understanding of the metabolic fate of the drug.

Download our poster from ISSX 2014 titled, 'Flexible strategies for the conduct of human metabolism studies with oncology molecules'.

There is an unmet need in the industry for a more efficient and flexible approach to providing drug product for early clinical studies. Presented here is an innovative approach to overcome these challenges by utilizing a real-time, adaptive manufacturing and supply platform.

Download our poster titled, 'Adaptive Manufacturing: A New Paradigm to Improve Efficiency and Effectiveness in Early Oncology Development.'

Download our scientific poster titled, 'Intravenous studies in man: Teasing apart absorption and clearance drivers of pharmacokinetic variability and dose and time-dependent non-linearity'.

With the first generation of biotherapeutics agents now nearing or having reached patent expiry, the potential for follow-on biotherapeutics is now presenting industry and regulatory bodies with novel challenges.

Download Quotient Sciences' scientific poster resource entitled 'Biosimilars: A Transatlantic Drift?' and contact our experts today to find out more.

Download our poster, 'Intravenous and Oral Microdose Pharmacokinetics of Three Novel Inhibitors of FabI in Healthy Subjects'.